IDEXX LABORATORIES (IDXX) — TRADE BRIEF

SETUP

IDXX is breaking above $563.88 on 1.3x average volume, clearing a level that had served as recent resistance. Price gapped higher off the prior close of $559.38, and the breakout is holding near signal price. The stock is recovering from a significant drawdown off its 52-week high of $769.98, currently sitting roughly 26% below that peak, so this move represents a potential base-building breakout rather than a momentum chase at highs. Risk is well-defined at $553.48 with roughly 1.5% downside to stop.

CATALYSTS

IDXX just beat Q1 2025 estimates by 3.8%, marking five consecutive earnings beats with a consistent pattern of 4-9% upside surprises. The recent embedding of SDMA early kidney disease detection into its flagship Catalyst test profile expands diagnostic utility and could lift test attach rates meaningfully. Pet healthcare spending has shown resilience even in softer macro environments. Long-term secular tailwinds around pet ownership and companion animal diagnostics remain intact.

RISKS

The risk/reward at 1:1.48 is acceptable but not exceptional for a high-beta name sitting well below its yearly highs. BofA flagged slower InVue installations as a near-term headwind, which could weigh on instrument revenue. Beta of 1.57 means macro volatility hits IDXX harder than the broader market. The P/E of 41.6x leaves limited margin for error if growth softens. Next earnings are not until August 2026, so there is no near-term catalyst to accelerate the move. Insider activity shows mostly small director share acquisitions, not aggressive buying, which is neutral at best. A broader market selloff or healthcare sector rotation could easily push price back below the breakout level.

CONVICTION: Medium

Five consecutive earnings beats and a clean breakout above resistance are positives, but the underwhelming risk/reward, elevated valuation, BofA's near-term headwind warning, and the stock's distance from its highs limit confidence in a sustained upside move from this level.